Want to see SCNX full AI Analyst Report?
Top Page
Scienture Holdings
(NASDAQ:SCNX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.00
▲(689.47% Upside)
Action:Upgraded
Date:10/19/26
The score is held down primarily by severe losses and heavy cash burn in the financials, alongside strongly bearish technical signals with the stock trading far below key moving averages. A positive offset comes from the Nasdaq compliance update and sharp sequential revenue growth tied to commercialization, but valuation support is limited due to negative earnings and no indicated dividend yield.
Positive Factors
Revenue Growth
The 71.94% trailing-twelve-month revenue increase indicates that Scienture is expanding its commercial base despite remaining unprofitable. Sustained sales growth would improve operating leverage over time, strengthen partner and channel economics, and provide a foundation for scaling its specialty pharmaceutical portfolio.
Negative Factors
Persistent Losses
Deeply negative net, EBIT, and EBITDA margins show that current revenue is not sufficient to cover Scienture’s operating cost structure. Until sales scale materially or expenses decline, the company may struggle to convert commercial growth into sustainable earnings and could remain financially dependent on outside capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The 71.94% trailing-twelve-month revenue increase indicates that Scienture is expanding its commercial base despite remaining unprofitable. Sustained sales growth would improve operating leverage over time, strengthen partner and channel economics, and provide a foundation for scaling its specialty pharmaceutical portfolio.
Read all positive factors
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.29M
Dividend Yield24.3%
Average Volume (3M)302.00K
Price to Earnings (P/E)―
Beta (1Y)2.75
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-46.25
Shares Outstanding1,642,565
10 Day Avg. Volume39,698
30 Day Avg. Volume302,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio-5.85
Enterprise Value/Market Cap3.09
Enterprise Value/Revenue19.93
Enterprise Value/Gross Profit64.84
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$6.00Price Target Upside1478.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.75
Revenue Forecast (FY)$4.79M
Scienture Holdings Business Overview & Revenue Model
Company Description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, a...
How the Company Makes Money
Scienture Holdings makes money primarily by commercializing pharmaceutical products and capturing economics from those products once they are approved and launched. Key revenue streams may include: (1) product sales (directly and/or via partners) ...
Scienture Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 821.32K | 431.61K | 136.64K | 1.36M | 10.25M | 9.89M |
| Gross Profit | 252.43K | 331.48K | 6.00K | 49.03K | 5.52M | 4.75M |
| EBITDA | -35.64M | -38.93M | -17.39M | -6.29M | -1.87M | -5.15M |
| Net Income | -37.95M | -41.51M | 9.07M | -17.84M | -3.47M | -5.32M |
Balance Sheet | ||||||
| Total Assets | 87.73M | 84.18M | 104.85M | 12.53M | 3.71M | 5.77M |
| Cash, Cash Equivalents and Short-Term Investments | 8.19M | 6.66M | 308.10K | 314.00 | 1.09M | 3.12M |
| Total Debt | 10.69M | 24.14K | 3.53M | 6.76M | 1.58M | 1.25M |
| Total Liabilities | 23.63M | 14.06M | 25.78M | 11.99M | 3.37M | 2.00M |
| Stockholders Equity | 64.10M | 70.12M | 79.07M | 542.35K | 763.14K | 3.77M |
Cash Flow | ||||||
| Free Cash Flow | -14.44M | -13.38M | -14.28M | -2.23M | -1.56M | -2.59M |
| Operating Cash Flow | -14.44M | -13.38M | -14.27M | -2.23M | -1.56M | -2.57M |
| Investing Cash Flow | 0.00 | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K |
| Financing Cash Flow | 25.63M | 19.73M | -12.98M | 1.41M | -35.17K | -208.18K |
Scienture Holdings Technical Analysis
Negative
0.38
Price Trends
6.33
Negative
8.01
Negative
9.19
Negative
Market Momentum
-0.86
Negative
31.96
Neutral
78.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 3.36, below the 50-day MA of 6.33, and below the 200-day MA of 9.19, indicating a bearish trend. The MACD of -0.86 indicates Negative momentum. The RSI at 31.96 is Neutral, neither overbought nor oversold. The STOCH value of 78.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNX.
Scienture Holdings Risk Analysis
Scienture Holdings disclosed 45 risk factors in its most recent earnings report. Scienture Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scienture Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $772.16M | 72.24 | 3.01% | ― | 12.93% | ― | |
53 Neutral | $127.18M | -0.46 | -129.70% | ― | -7.54% | -143.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.43M | -0.05 | -400.87% | ― | -9.31% | 89.42% | |
42 Neutral | $5.29M | -0.07 | -53.51% | 24.30% | ― | ― |
* Healthcare Sector Average
SCNX
Scienture Holdings
3.22
-16.18
-83.40%
PHR
Phreesia
12.44
-10.20
-45.05%
HCAT
Health Catalyst
1.69
-1.54
-47.68%
ONMD
OneMedNet
4.22
-16.98
-80.09%
VSEE
VSee Health
1.78
-76.22
-97.72%
BFRG
BullFrog AI Holdings, Inc.
0.49
-0.79
-61.95%
Scienture Holdings Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Scienture Holdings Regains Nasdaq Compliance Amid Revenue Surge
Positive
Oct 19, 2026
Scienture Holdings, Inc., a Nasdaq-listed specialty pharmaceutical holding company, reported strong commercial momentum in the third quarter of 2026 driven by its two FDA-approved products, Arbli™ and REZENOPY™. The firm is focused on ...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Scienture Holdings Executes Reverse Stock Split to Retain Listing
Neutral
Oct 7, 2026
Scienture Holdings implemented a 1-for-25 reverse stock split of its common stock, following board approval on September 17, 2026 and effectiveness at 12:01 a.m. Eastern Time on October 5, 2026. The move reduced shares outstanding from 41,064,146 ...
Business Operations and StrategyRegulatory Filings and Compliance
Scienture Holdings Updates Investor Presentation and Guidance
Neutral
Sep 14, 2026
On September 14, 2026, Scienture Holdings posted a revised investor presentation on its website, which it plans to use in meetings with analysts, potential investors and other stakeholders. The materials are expressly furnished rather than filed u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.